The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats

Neuroscience Letters

Volumn 469, Issue 1, 2010, Pages 127-130

  Yang, Shii Yi ^a   Hong, Chen Jee ^a,b   Huang, Yn Ho ^a   Tsai, Shih Jen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

c Fos; Clozapine; Ketamine; Prepulse inhibition; Sarcosine

Indexed keywords

CLOZAPINE; GLYCINE TRANSPORTER 1; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN C FOS; SARCOSINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG PROTEIN BINDING; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; KETAMINE; MOTOR ACTIVITY; NEURAL INHIBITION; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE; SCHIZOPHRENIA; STARTLE REACTION;

EID: 72649084912     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.11.058     Document Type: Article

References (27)

1. Amara S.G., and Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16 (1993) 73-93
2. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
3. Becker A., and Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 1267-1277
4. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15730-15734
5. Campos A.R., Santos F.A., and Rao V.S. Ketamine-induced potentiation of morphine analgesia in rat tail-flick test: role of opioid-, alpha2-adrenoceptors and ATP-sensitive potassium channels. Biol. Pharm. Bull. 29 (2006) 86-89
6. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol. Neurobiol. 26 (2006) 365-384
7. Feifel D., Melendez G., and Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29 (2004) 731-738
8. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., and Coyle J.T. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56 (1999) 21-27
9. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151 (1994) 1234-1236
10. Javitt D.C. Glycine modulators in schizophrenia. Curr. Opin. Invest. Drugs 3 (2002) 1067-1072
11. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
12. Kim K.M., Kingsmore S.F., Han H., Yang-Feng T.L., Godinot N., Seldin M.F., Caron M.G., and Giros B. Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol. Pharmacol. 45 (1994) 608-617
13. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994) 199-214
14. V. Labrie, J.C. Roder, The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia, Neurosci. Biobehav. Rev., in press.
15. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62 (2005) 1196-1204
16. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., Chen P.W., and Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60 (2006) 645-649
17. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Liau C.H., Perng C.H., and Tsai G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 63 (2008) 9-12
18. Mansbach R.S., and Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2 (1989) 299-308
19. Millan M.J. N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 191-213
20. Moberg P.J., and Turetsky B.I. Scent of a disorder: olfactory functioning in schizophrenia. Curr. Psychiatry Rep. 5 (2003) 311-319
21. Rosse R.B., Collins Jr. J.P., Fay-McCarthy M., Alim T.N., Wyatt R.T., and Deutsch S.I. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin. Neuropharmacol. 17 (1994) 359-369
22. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24 (1998) 285-301
23. Tamminga C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry Suppl. 37 (1999) 12-15
24. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55 (2004) 452-456
25. Tsai G., Ralph-Williams R.J., Martina M., Bergeron R., Berger-Sweeney J., Dunham K.S., Jiang Z., Caine S.B., and Coyle J.T. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8485-8490
26. Turetsky B.I., Moberg P.J., Arnold S.E., Doty R.L., and Gur R.E. Low olfactory bulb volume in first-degree relatives of patients with schizophrenia. Am. J. Psychiatry 160 (2003) 703-708
27. Turetsky B.I., Moberg P.J., Yousem D.M., Doty R.L., Arnold S.E., and Gur R.E. Reduced olfactory bulb volume in patients with schizophrenia. Am. J. Psychiatry 157 (2000) 828-830